Digital RESI November at a Glance

18 Nov

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Digital RESI November is not over yet but has so far been one of our most successful virtual events. With over 600 attendees from 30 countries across 5 continents, RESI continues to demonstrate how truly global Life Science Nation (LSN)’s early-stage ecosystem is. Attendees have had access to investor panels, workshops and could watch over 50 presenting companies in the Innovator’s Pitch Challenge. With two days down and one day left, over 1,000 meetings have already taken place through RESI’s unique, match-based partnering platform. With our next RESI, taking place during JP Morgan Healthcare Week, right around the corner, make sure not to miss out on the next opportunity to take part in a virtual event that truly works! Sign up by November 28 to save $300!


Digital RESI at JPM

11 Nov

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Digital Redefining Early Stage Investment (RESI) returns to JP Morgan in its successful virtual format January 11-13, 2022! JPM Week is the World Series of early-stage life science and healthcare, bringing innovators, investors, and industry experts together to build relationships and make deals, which makes it a highly competitive event.

Digital RESI levels the playing field by offering quality content and compelling programs, like the Innovator’s Pitch Challenge, and match-based partnering fraction of the cost of the other partnering conferences.

DIGITAL RESI
@JPM		 OTHER PARTNERING EVENTS (Virtual)
@JPM SPRING
Registration $895 $1,795 €1,995
Registration + Pitch Fee $1,695 $5,745 €2,240

*Prices as of today

The team at Life Science Nation understands the financial, logistical, and other non-tangible barriers to entry when it comes to early-stage fundraising. This is why Digital RESI is affordable, accessible, and designed to connect partnerships that are based on product fit and stage of development. To ensure founders are set up for optimal success, we also feature several complimentary fundraising bootcamps available to the public to introduce founders to our system, as well as provide resources and proven strategies to help them get started on the right foot!

Get to know your business development representative to learn what Digital RESI has to offer you on your unique fundraising journey and sign up for Digital RESI JPM, January 11-13 by November 28 to save $300 on super early bird rates.

Register-now-button-new

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International East Coast (USA) & China Midwest (USA)
& Canada		 West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting		 Candice He
Vice President of Business Development, Global Investment Strategist
Book a Meeting		 Antoinette Lowre
Manager of Business Development
Book a Meeting		 Alexander Vassallo
Manager of Business Development
Book a Meeting

Digital RESI November Final Agenda

11 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

It’s been a busy week at Life Science Nation! As the audience chatters and orchestra buzzes in the moments before curtain opens on a show, the week before Digital RESI November 16-18 has been filled with booking meetings, partnering tutorials, panel planning calls, and putting the finishing touches on pitch materials. The energy is in the air and there’s nothing like it!

Check out some of the content coming to you virtually through Digital RESI November next week. Each session has been carefully crafted to highlight the best in early-stage life science and healthcare, and every feature is designed to connect fundraising founders with investors and strategic partners who are a fit for their product and stage of development.

  Tuesday (11/16) Wednesday (11/17) Thursday (11/18)
 
All Day Partnering
10AM EST Innovator’s Pitch Challenge #1 Diagnostics First Republic Bank Workshop – How to Evaluate Your Banking Partner Innovator’s Pitch Challenge #9 Longevity – Medical Devices
Innovator’s Pitch Challenge #5 Oncology Therapeutics
11AM EST Oncology Innovation Panel Cognitive Care Panel Digital Health Panel
Innovator’s Pitch Challenge #2 Medical Devices Innovator’s Pitch Challenge #10 Therapeutics
12PM EST TriNet Workshop – Piecing Together the Talent Puzzle MWE Workshop – Negotiating Term Sheets Burns & Levinson Licensing Workshop
1PM EST Innovator’s Pitch Challenge #3 R&D/Therapeutics Innovator’s Pitch Challenge #6 AI – Drug Discovery Innovator’s Pitch Challenge #11 Novel Drug Delivery
Tales from the Road: AI Innovators on their Fundraising Journey
2PM EST AI-Assisted Remote Care & Chronic Disease Management Panel Investing in Precision Medicine Panel Women in Age-Tech Panel
3PM EST MedTech Strategics Panel Clinical & Research Data Panel Impact Investors Panel
4PM EST Tales from the Road: Age-Tech Innovators on their Fundraising Journey Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey  
Innovator’s Pitch Challenge #7 Longevity – Therapeutics & Digital Health
5PM EST Angels & Family Offices Panel Innovator’s Pitch Challenge #8 Medical Devices  
Innovator’s Pitch Challenge #4 AI – Medical Devices & Digital Health

If you haven’t yet signed up for Digital RESI November, sign up now! There is still time, but meeting slots are booking up fast. If you’re already looking ahead to 2022, sign up for Digital RESI JPM early to save on super early bird rates!

RESI-NOV-Banner-3050x-1050

Embracing the Early-Stage Journey

11 Nov

By Rory McCann, Marketing Manager & Conference Producer, LSN

David Dlesk is a seasoned entrepreneur and investor, passionate about therapeutic innovation, which has led him to co-found Embrace Prevention Care, a company dedicated to safe and effective medication adherence for older adults. David has decades of experience in early-stage life science and healthcare, and has learned how to lead, connect, and accept sound advice. Listen to our recent conversation and join David at Digital RESI November, where he’ll be featured on the Tales from the Road: Age-Tech Innovators on their Fundraising Journey panel on November 16 at 4 PM EST. If you’re an early-stage fundraising executive, there’s still time to sign up and book meetings!

RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: Venture Arm of Global Services Firm Invests in Software-Based Technologies in the Healthcare Sector, Focusing on Seed to Series A Companies Globally

11 Nov

A venture fund of a global firm that provides software-based services to multiple industries, including healthcare and the life sciences does both venture investing and forms strategic partnerships with companies that are aligned with the firm’s current or future services. As an investor, the firm will generally invest between $200K-3M in seed-series A rounds. For partnerships, the firm is looking for companies looking to scale, potentially working in concert to build clients. The firm will invest and partner globally.

The firm invests in companies developing software-based technologies. Examples of the firm’s services include software for healthcare, such as hospital automation and clinical workflow, as well as virtual care and medical adherence, among others. In the life sciences space, the firm is interested in technologies such as software for connected devices, AI/ML platforms for drug discovery, as well as cell or gene therapies, or decentralized clinical trials, as examples.

The firm is only interested in companies that represent a strategic fit, either for currently offered services, or for complementary services that could expand the firm’s portfolio of services.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based VC With Newly Launched Fund Invests Up to $10M CAD in Therapeutics, Devices, Precision Medicine, and More

11 Nov

A venture capital firm with offices in Canada was founded by a team with a successful track record of identifying, building, and growing life science companies. The firm recently launched a new fund through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Fund Seeks Global Early-Stage Investment Opportunities in Life Sciences with Strong Interests in Platform Technologies

11 Nov

An early stage VC fund formed by alumni of a top tier university currently has $100M under management and focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →